Literature DB >> 30508607

Behavioral effects of psychostimulants in mutant mice with cell-type specific deletion of CB2 cannabinoid receptors in dopamine neurons.

Ana Canseco-Alba1, Norman Schanz1, Branden Sanabria1, Juan Zhao2, Zhicheng Lin2, Qing-Rong Liu3, Emmanuel S Onaivi4.   

Abstract

Activation of the endocannabinoid system modulate dopaminergic pathways that are involved in the effects of psychostimulants including amphetamine, cocaine, nicotine and other drugs of abuse. Genetic deletion or pharmacological activation of CB2 cannabinoid receptor is involved in the modulation of the effects of psychostimulants and their rewarding properties. Here we report on the behavioral effects of psychostimulants in DAT-Cnr2 conditional knockout (cKO) mice with selective deletion of type 2 cannabinoid receptors in dopamine neurons. There was enhanced psychostimulant induced hyperactivity in DAT-Cnr2 cKO mice, but the psychostimulant-induced sensitization was absent in DAT-Cnr2 cKO compared to the WT mice. Intriguingly, lower doses of amphetamine reduced locomotor activity of the DAT-Cnr2 cKO mice. While cocaine, amphetamine and methamphetamine produced robust conditioned place preference (CPP) in both DAT-Cnr2 cKO and WT mice, nicotine at the dose used induced CPP only in the WT but not in the DAT-Cn2 cKO mice. However, pre-treatment with the CB2R selective agonist JWH133, blocked cocaine and nicotine induced CPP in the WT mice. The deletion of CB2Rs in dopamine neurons modified the levels of tyrosine hydroxylase, and reduced the expression of dopamine transporter gene expression in DAT-Cnr2 cKO midbrain region. Taken together, our data suggest that CB2Rs play a role in the modulation of dopamine-related effects of psychostimulants and could be exploited as therapeutic target in psychostimulant addiction and other psychiatric disorders associated with dopamine dysregulation. Published by Elsevier B.V.

Entities:  

Keywords:  Amphetamine; CB2 cannabinoid receptors; Cocaine; Conditioned place preference; Mice; Nicotine

Mesh:

Substances:

Year:  2018        PMID: 30508607      PMCID: PMC6327973          DOI: 10.1016/j.bbr.2018.11.043

Source DB:  PubMed          Journal:  Behav Brain Res        ISSN: 0166-4328            Impact factor:   3.332


  58 in total

Review 1.  Psychopharmacology of conditioned reward: evidence for a rewarding signal at D1-like dopamine receptors.

Authors:  M A Sutton; R J Beninger
Journal:  Psychopharmacology (Berl)       Date:  1999-05       Impact factor: 4.530

2.  Involvement of cannabinoid CB1 and CB2 receptor activity in the development of behavioural sensitization to methamphetamine effects in mice.

Authors:  Leos Landa; Alexandra Sulcova; Karel Slais
Journal:  Neuro Endocrinol Lett       Date:  2006 Feb-Apr       Impact factor: 0.765

Review 3.  Endocannabinoid signaling system and brain reward: emphasis on dopamine.

Authors:  Eliot L Gardner
Journal:  Pharmacol Biochem Behav       Date:  2005-06       Impact factor: 3.533

4.  Strain-dependent performance in nicotine-induced conditioned place preference.

Authors:  Munir G Kutlu; Leonardo A Ortega; Thomas J Gould
Journal:  Behav Neurosci       Date:  2014-12-29       Impact factor: 1.912

Review 5.  Marijuana and cannabinoid regulation of brain reward circuits.

Authors:  Carl R Lupica; Arthur C Riegel; Alexander F Hoffman
Journal:  Br J Pharmacol       Date:  2004-08-16       Impact factor: 8.739

6.  Attenuation of basal and cocaine-enhanced locomotion and nucleus accumbens dopamine in cannabinoid CB1-receptor-knockout mice.

Authors:  Xia Li; Alexander F Hoffman; Xiao-Qing Peng; Carl R Lupica; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Psychopharmacology (Berl)       Date:  2008-12-20       Impact factor: 4.530

7.  Increased mortality, hypoactivity, and hypoalgesia in cannabinoid CB1 receptor knockout mice.

Authors:  A Zimmer; A M Zimmer; A G Hohmann; M Herkenham; T I Bonner
Journal:  Proc Natl Acad Sci U S A       Date:  1999-05-11       Impact factor: 11.205

8.  Identification of the sites of 2-arachidonoylglycerol synthesis and action imply retrograde endocannabinoid signaling at both GABAergic and glutamatergic synapses in the ventral tegmental area.

Authors:  Ferenc Mátyás; Gabriella M Urbán; Masahiko Watanabe; Ken Mackie; Andreas Zimmer; Tamás F Freund; István Katona
Journal:  Neuropharmacology       Date:  2007-06-22       Impact factor: 5.250

9.  Attenuation of Cocaine-Induced Conditioned Place Preference and Motor Activity via Cannabinoid CB2 Receptor Agonism and CB1 Receptor Antagonism in Rats.

Authors:  Foteini Delis; Alexia Polissidis; Nafsika Poulia; Zuzana Justinova; George G Nomikos; Steven R Goldberg; Katerina Antoniou
Journal:  Int J Neuropsychopharmacol       Date:  2017-03-01       Impact factor: 5.176

10.  Role of endocannabinoids in regulating drug dependence.

Authors:  Daniela Parolaro; Daniela Vigano; Natalia Realini; Tiziana Rubino
Journal:  Neuropsychiatr Dis Treat       Date:  2007-12       Impact factor: 2.570

View more
  25 in total

1.  Xie2-64, a novel CB2 receptor inverse agonist, reduces cocaine abuse-related behaviors in rodents.

Authors:  Chloe J Jordan; Zhi-Wei Feng; Ewa Galaj; Guo-Hua Bi; Ying Xue; Ying Liang; Terence McGuire; Xiang-Qun Xie; Zheng-Xiong Xi
Journal:  Neuropharmacology       Date:  2020-07-24       Impact factor: 5.250

2.  Δ8 -Tetrahydrocannabivarin has potent anti-nicotine effects in several rodent models of nicotine dependence.

Authors:  Zheng-Xiong Xi; Pretal Muldoon; Xiao-Fei Wang; Guo-Hua Bi; M Imad Damaj; Aron H Lichtman; Roger G Pertwee; Eliot L Gardner
Journal:  Br J Pharmacol       Date:  2019-10-28       Impact factor: 8.739

3.  Psychiatric Disorders and Cannabinoid Receptors.

Authors:  Neal Joshi; Emmanuel S Onaivi
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

Review 4.  Progress in brain cannabinoid CB2 receptor research: From genes to behavior.

Authors:  Chloe J Jordan; Zheng-Xiong Xi
Journal:  Neurosci Biobehav Rev       Date:  2019-01-03       Impact factor: 8.989

Review 5.  Molecular Alterations of the Endocannabinoid System in Psychiatric Disorders.

Authors:  Daniela Navarro; Ani Gasparyan; Francisco Navarrete; Abraham B Torregrosa; Gabriel Rubio; Marta Marín-Mayor; Gabriela B Acosta; Maria Salud Garcia-Gutiérrez; Jorge Manzanares
Journal:  Int J Mol Sci       Date:  2022-04-26       Impact factor: 6.208

Review 6.  Potential of Cannabinoid Receptor Ligands as Treatment for Substance Use Disorders.

Authors:  Ewa Galaj; Zheng-Xiong Xi
Journal:  CNS Drugs       Date:  2019-10       Impact factor: 5.749

7.  Beta-caryophyllene inhibits cocaine  addiction-related behavior by activation of PPARα and PPARγ: repurposing a FDA-approved food additive for cocaine use disorder.

Authors:  Ewa Galaj; Guo-Hua Bi; Allamar Moore; Kai Chen; Yi He; Eliot Gardner; Zheng-Xiong Xi
Journal:  Neuropsychopharmacology       Date:  2020-10-17       Impact factor: 7.853

8.  Dissecting the role of CB1 and CB2 receptors in cannabinoid reward versus aversion using transgenic CB1- and CB2-knockout mice.

Authors:  Xia Li; Briana J Hempel; Hong-Ju Yang; Xiao Han; Guo-Hua Bi; Eliot L Gardner; Zheng-Xiong Xi
Journal:  Eur Neuropsychopharmacol       Date:  2020-12-15       Impact factor: 4.600

9.  Repeated cocaine administration upregulates CB2 receptor expression in striatal medium-spiny neurons that express dopamine D1 receptors in mice.

Authors:  Hai-Ying Zhang; Lindsay De Biase; Ramesh Chandra; Hui Shen; Qing-Rong Liu; Eliot Gardner; Mary Kay Lobo; Zheng-Xiong Xi
Journal:  Acta Pharmacol Sin       Date:  2021-07-27       Impact factor: 6.150

10.  β-Caryophyllene, a dietary terpenoid, inhibits nicotine taking and nicotine seeking in rodents.

Authors:  Yi He; Ewa Galaj; Guo-Hua Bi; Xiao-Fei Wang; Eliot Gardner; Zheng-Xiong Xi
Journal:  Br J Pharmacol       Date:  2020-02-15       Impact factor: 9.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.